Global Neurological Biomarkers Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031

Summary

A biomarker is a characteristic that can be objectively measured and evaluated as an indicator of a physiological as well as a pathological process or pharmacological response to a therapeutic intervention. Examples of classical biomarkers are measurable alterations in blood pressure and blood glucose in diabetes mellitus.

According to APO Research, The global Neurological Biomarkers market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Neurological Biomarkers is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Neurological Biomarkers is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Neurological Biomarkers is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Neurological Biomarkers is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Neurological Biomarkers include Thermo Fisher Scientific, Merck, Quest Diagnostics, Abbott, Roche, Illumina, Bio-Rad Laboratories, QIAGEN and Myriad RBM, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Neurological Biomarkers, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Neurological Biomarkers, also provides the sales of main regions and countries. Of the upcoming market potential for Neurological Biomarkers, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Neurological Biomarkers sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Neurological Biomarkers market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Neurological Biomarkers sales, projected growth trends, production technology, application and end-user industry.


Neurological Biomarkers Segment by Company

Thermo Fisher Scientific
Merck
Quest Diagnostics
Abbott
Roche
Illumina
Bio-Rad Laboratories
QIAGEN
Myriad RBM
Cisbio Bioassays
Athena Diagnostics
BGI
Wuxi APP
Aepodia
Proteome Sciences
Genewiz

Neurological Biomarkers Segment by Type

Proteomics
Genomics
Imaging
Bioinformatics
Others

Neurological Biomarkers Segment by Application

Diagnostics
Drug Discovery
Personalized Medicine
Others

Neurological Biomarkers Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neurological Biomarkers market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Neurological Biomarkers and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neurological Biomarkers.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Neurological Biomarkers market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Neurological Biomarkers manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Neurological Biomarkers in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Neurological Biomarkers in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.


1 Market Overview
1.1 Product Definition
1.2 Global Neurological Biomarkers Market Size, 2020 VS 2024 VS 2031
1.3 Global Neurological Biomarkers Market Size Estimates and Forecasts (2020-2031)
1.4 Global Neurological Biomarkers Sales Estimates and Forecasts (2020-2031)
1.5 Global Neurological Biomarkers Market Average Price (2020-2031)
1.6 Assumptions and Limitations
1.7 Study Goals and Objectives
2 Global Neurological Biomarkers Market Dynamics
2.1 Neurological Biomarkers Industry Trends
2.2 Neurological Biomarkers Industry Drivers
2.3 Neurological Biomarkers Industry Opportunities and Challenges
2.4 Neurological Biomarkers Industry Restraints
3 Neurological Biomarkers Market by Manufacturers
3.1 Global Neurological Biomarkers Revenue by Manufacturers (2020-2025)
3.2 Global Neurological Biomarkers Sales by Manufacturers (2020-2025)
3.3 Global Neurological Biomarkers Average Sales Price by Manufacturers (2020-2025)
3.4 Global Neurological Biomarkers Industry Manufacturers Ranking, 2023 VS 2024 VS 2025
3.5 Global Neurological Biomarkers Key Manufacturers Manufacturing Sites & Headquarters
3.6 Global Neurological Biomarkers Manufacturers, Product Type & Application
3.7 Global Neurological Biomarkers Manufacturers Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global Neurological Biomarkers Market CR5 and HHI
3.8.2 Global Top 5 and 10 Neurological Biomarkers Players Market Share by Revenue in 2024
3.8.3 2024 Neurological Biomarkers Tier 1, Tier 2, and Tier 3
4 Neurological Biomarkers Market by Type
4.1 Neurological Biomarkers Type Introduction
4.1.1 Proteomics
4.1.2 Genomics
4.1.3 Imaging
4.1.4 Bioinformatics
4.1.5 Others
4.2 Global Neurological Biomarkers Sales by Type
4.2.1 Global Neurological Biomarkers Sales by Type (2020 VS 2024 VS 2031)
4.2.2 Global Neurological Biomarkers Sales by Type (2020-2031)
4.2.3 Global Neurological Biomarkers Sales Market Share by Type (2020-2031)
4.3 Global Neurological Biomarkers Revenue by Type
4.3.1 Global Neurological Biomarkers Revenue by Type (2020 VS 2024 VS 2031)
4.3.2 Global Neurological Biomarkers Revenue by Type (2020-2031)
4.3.3 Global Neurological Biomarkers Revenue Market Share by Type (2020-2031)
5 Neurological Biomarkers Market by Application
5.1 Neurological Biomarkers Application Introduction
5.1.1 Diagnostics
5.1.2 Drug Discovery
5.1.3 Personalized Medicine
5.1.4 Others
5.2 Global Neurological Biomarkers Sales by Application
5.2.1 Global Neurological Biomarkers Sales by Application (2020 VS 2024 VS 2031)
5.2.2 Global Neurological Biomarkers Sales by Application (2020-2031)
5.2.3 Global Neurological Biomarkers Sales Market Share by Application (2020-2031)
5.3 Global Neurological Biomarkers Revenue by Application
5.3.1 Global Neurological Biomarkers Revenue by Application (2020 VS 2024 VS 2031)
5.3.2 Global Neurological Biomarkers Revenue by Application (2020-2031)
5.3.3 Global Neurological Biomarkers Revenue Market Share by Application (2020-2031)
6 Global Neurological Biomarkers Sales by Region
6.1 Global Neurological Biomarkers Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Neurological Biomarkers Sales by Region (2020-2031)
6.2.1 Global Neurological Biomarkers Sales by Region (2020-2025)
6.2.2 Global Neurological Biomarkers Sales Forecasted by Region (2025-2030)
6.3 North America
6.3.1 North America Neurological Biomarkers Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.3.2 North America Neurological Biomarkers Sales by Country (2020-2031)
6.3.3 U.S.
6.3.4 Canada
6.3.5 Mexico
6.4 Europe
6.4.1 Europe Neurological Biomarkers Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.4.2 Europe Neurological Biomarkers Sales by Country (2020-2031)
6.4.3 Germany
6.4.4 France
6.4.5 U.K.
6.4.6 Italy
6.4.7 Netherlands
6.5 Asia Pacific
6.5.1 Asia Pacific Neurological Biomarkers Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.5.2 Asia Pacific Neurological Biomarkers Sales by Country (2020-2031)
6.5.3 China
6.5.4 Japan
6.5.5 South Korea
6.5.6 Southeast Asia
6.5.7 India
6.5.8 Australia
6.6 South America, Middle East and Africa
6.6.1 South America, Middle East and Africa Neurological Biomarkers Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.6.2 South America, Middle East and Africa Neurological Biomarkers Sales by Country (2020-2031)
6.6.3 Brazil
6.6.4 South Africa
6.6.5 Saudi Arabia
6.6.6 Turkey
6.6.6 Argentina
6.6.6 UAE
6.6.6 Egypt
6.6.6 Chile
7 Global Neurological Biomarkers Revenue by Region
7.1 Global Neurological Biomarkers Revenue by Region
7.1.1 Global Neurological Biomarkers Revenue by Region: 2020 VS 2024 VS 2031
7.1.2 Global Neurological Biomarkers Revenue by Region (2020-2025)
7.1.3 Global Neurological Biomarkers Revenue by Region (2026-2031)
7.1.4 Global Neurological Biomarkers Revenue Market Share by Region (2020-2031)
7.2 North America
7.2.1 North America Neurological Biomarkers Revenue (2020-2031)
7.2.2 North America Neurological Biomarkers Revenue Share by Country: 2020 VS 2024 VS 2031
7.3 Europe
7.3.1 Europe Neurological Biomarkers Revenue (2020-2031)
7.3.2 Europe Neurological Biomarkers Revenue Share by Country: 2020 VS 2024 VS 2031
7.4 Asia-Pacific
7.4.1 Asia-Pacific Neurological Biomarkers Revenue (2020-2031)
7.4.2 Asia-Pacific Neurological Biomarkers Revenue Share by Country: 2020 VS 2024 VS 2031
7.5 South America, Middle East and Africa
7.5.1 South America, Middle East and Africa Neurological Biomarkers Revenue (2020-2031)
7.5.2 South America, Middle East and Africa Neurological Biomarkers Revenue Share by Country: 2020 VS 2024 VS 2031
8 Company Profiles
8.1 Thermo Fisher Scientific
8.1.1 Thermo Fisher Scientific Comapny Information
8.1.2 Thermo Fisher Scientific Business Overview
8.1.3 Thermo Fisher Scientific Neurological Biomarkers Sales, Price, Revenue and Gross Margin (2020-2025)
8.1.4 Thermo Fisher Scientific Neurological Biomarkers Product Portfolio
8.1.5 Thermo Fisher Scientific Recent Developments
8.2 Merck
8.2.1 Merck Comapny Information
8.2.2 Merck Business Overview
8.2.3 Merck Neurological Biomarkers Sales, Price, Revenue and Gross Margin (2020-2025)
8.2.4 Merck Neurological Biomarkers Product Portfolio
8.2.5 Merck Recent Developments
8.3 Quest Diagnostics
8.3.1 Quest Diagnostics Comapny Information
8.3.2 Quest Diagnostics Business Overview
8.3.3 Quest Diagnostics Neurological Biomarkers Sales, Price, Revenue and Gross Margin (2020-2025)
8.3.4 Quest Diagnostics Neurological Biomarkers Product Portfolio
8.3.5 Quest Diagnostics Recent Developments
8.4 Abbott
8.4.1 Abbott Comapny Information
8.4.2 Abbott Business Overview
8.4.3 Abbott Neurological Biomarkers Sales, Price, Revenue and Gross Margin (2020-2025)
8.4.4 Abbott Neurological Biomarkers Product Portfolio
8.4.5 Abbott Recent Developments
8.5 Roche
8.5.1 Roche Comapny Information
8.5.2 Roche Business Overview
8.5.3 Roche Neurological Biomarkers Sales, Price, Revenue and Gross Margin (2020-2025)
8.5.4 Roche Neurological Biomarkers Product Portfolio
8.5.5 Roche Recent Developments
8.6 Illumina
8.6.1 Illumina Comapny Information
8.6.2 Illumina Business Overview
8.6.3 Illumina Neurological Biomarkers Sales, Price, Revenue and Gross Margin (2020-2025)
8.6.4 Illumina Neurological Biomarkers Product Portfolio
8.6.5 Illumina Recent Developments
8.7 Bio-Rad Laboratories
8.7.1 Bio-Rad Laboratories Comapny Information
8.7.2 Bio-Rad Laboratories Business Overview
8.7.3 Bio-Rad Laboratories Neurological Biomarkers Sales, Price, Revenue and Gross Margin (2020-2025)
8.7.4 Bio-Rad Laboratories Neurological Biomarkers Product Portfolio
8.7.5 Bio-Rad Laboratories Recent Developments
8.8 QIAGEN
8.8.1 QIAGEN Comapny Information
8.8.2 QIAGEN Business Overview
8.8.3 QIAGEN Neurological Biomarkers Sales, Price, Revenue and Gross Margin (2020-2025)
8.8.4 QIAGEN Neurological Biomarkers Product Portfolio
8.8.5 QIAGEN Recent Developments
8.9 Myriad RBM
8.9.1 Myriad RBM Comapny Information
8.9.2 Myriad RBM Business Overview
8.9.3 Myriad RBM Neurological Biomarkers Sales, Price, Revenue and Gross Margin (2020-2025)
8.9.4 Myriad RBM Neurological Biomarkers Product Portfolio
8.9.5 Myriad RBM Recent Developments
8.10 Cisbio Bioassays
8.10.1 Cisbio Bioassays Comapny Information
8.10.2 Cisbio Bioassays Business Overview
8.10.3 Cisbio Bioassays Neurological Biomarkers Sales, Price, Revenue and Gross Margin (2020-2025)
8.10.4 Cisbio Bioassays Neurological Biomarkers Product Portfolio
8.10.5 Cisbio Bioassays Recent Developments
8.11 Athena Diagnostics
8.11.1 Athena Diagnostics Comapny Information
8.11.2 Athena Diagnostics Business Overview
8.11.3 Athena Diagnostics Neurological Biomarkers Sales, Price, Revenue and Gross Margin (2020-2025)
8.11.4 Athena Diagnostics Neurological Biomarkers Product Portfolio
8.11.5 Athena Diagnostics Recent Developments
8.12 BGI
8.12.1 BGI Comapny Information
8.12.2 BGI Business Overview
8.12.3 BGI Neurological Biomarkers Sales, Price, Revenue and Gross Margin (2020-2025)
8.12.4 BGI Neurological Biomarkers Product Portfolio
8.12.5 BGI Recent Developments
8.13 Wuxi APP
8.13.1 Wuxi APP Comapny Information
8.13.2 Wuxi APP Business Overview
8.13.3 Wuxi APP Neurological Biomarkers Sales, Price, Revenue and Gross Margin (2020-2025)
8.13.4 Wuxi APP Neurological Biomarkers Product Portfolio
8.13.5 Wuxi APP Recent Developments
8.14 Aepodia
8.14.1 Aepodia Comapny Information
8.14.2 Aepodia Business Overview
8.14.3 Aepodia Neurological Biomarkers Sales, Price, Revenue and Gross Margin (2020-2025)
8.14.4 Aepodia Neurological Biomarkers Product Portfolio
8.14.5 Aepodia Recent Developments
8.15 Proteome Sciences
8.15.1 Proteome Sciences Comapny Information
8.15.2 Proteome Sciences Business Overview
8.15.3 Proteome Sciences Neurological Biomarkers Sales, Price, Revenue and Gross Margin (2020-2025)
8.15.4 Proteome Sciences Neurological Biomarkers Product Portfolio
8.15.5 Proteome Sciences Recent Developments
8.16 Genewiz
8.16.1 Genewiz Comapny Information
8.16.2 Genewiz Business Overview
8.16.3 Genewiz Neurological Biomarkers Sales, Price, Revenue and Gross Margin (2020-2025)
8.16.4 Genewiz Neurological Biomarkers Product Portfolio
8.16.5 Genewiz Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Neurological Biomarkers Value Chain Analysis
9.1.1 Neurological Biomarkers Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Neurological Biomarkers Production Mode & Process
9.2 Neurological Biomarkers Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Neurological Biomarkers Distributors
9.2.3 Neurological Biomarkers Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
11.6 Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings